RecruitingPhase 2NCT06395753
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
A Phase 2, Randomized, Open-Label, Dose-Finding Study of Debio 4228, an Extended-Release Formulation of Gonadotropin-Releasing Hormone Antagonist in Participants With Advanced Prostate Cancer
Sponsor
Debiopharm International SA
Enrollment
66 participants
Start Date
May 23, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The primary purpose of this study is to determine the pharmacokinetics (PK) and pharmacodynamics (PD) of Debio 4228.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria9
- Participant with histologically confirmed diagnosis of prostate cancer, with one of the following:
- Newly diagnosed androgen-sensitive locally advanced or metastatic disease; or
- Localized disease not suitable for local primary intervention with curative intent.
- Participant judged by the Study Investigator to be candidate for continuous androgen deprivation therapy (ADT).
- Baseline morning serum testosterone levels \>150 ng/dL at screening visit.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Life expectancy of at least 6 months.
- Adequate bone marrow, hepatic, and renal function at the screening visit.
- \[Note: Other protocol and subprotocol-defined criteria apply\]
Exclusion Criteria9
- Previous ADT (neoadjuvant or adjuvant hormonal therapy) for ≥6 months duration and \<6 months treatment-free interval before start of screening.
- Participant requires combination with androgen deprivation therapy with the exception of enzalutamide.
- History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.
- Received chemotherapy or cryotherapy within 8 weeks prior to the start of screening for the treatment of prostate cancer.
- Abnormal cardiovascular function or diabetes.
- Use of exogenous testosterone within 6 months before the start of screening.
- Major surgery within 4 weeks before the start of screening.
- Cancer disease within the last two years except for prostate cancer and some skin cancers.
- \[Note: Other protocol and subprotocol-defined criteria apply\]
Interventions
DRUGDebio 4228
Administered as IM injection.
Locations(37)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06395753
Related Trials
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
NCT0678067052 locations